TD Private Client Wealth
AVXL icon

TD Private Client Wealth’s Anavex Life Sciences AVXL Stock Holding History

TD Private Client Wealth’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$463 Buy
+229
New +$633 ﹤0.01% 1655
2021
Q4 		– Sell
-33
Closed -$592 – 1173
2021
Q3 		$592 Hold
33
– – ﹤0.01% 1152
2021
Q2 		$754 Hold
33
– – ﹤0.01% 1143
2021
Q1 		$493 Buy
+33
New +$360 ﹤0.01% 1125

Other funds holding AVXL

Apella Capital
Apella Capital West Hartford, Connecticut $7.88B AUM 10.78% 1-Year Est. Return
PVG Asset Management
PVG Asset Management Golden, Colorado $147M AUM 52.72% 1-Year Est. Return
Hikari Power
Hikari Power Tokyo, Japan $439M AUM 11.38% 1-Year Est. Return
LexAurum Advisors
LexAurum Advisors Overland Park, Kansas $893M AUM
Sheets Smith Wealth Management
Sheets Smith Wealth Management Winston-Salem, North Carolina $958M AUM 21.88% 1-Year Est. Return
Opus Capital Group
Opus Capital Group Cincinnati, Ohio $1.02B AUM 13.75% 1-Year Est. Return
Forum Financial Management
Forum Financial Management Lombard, Illinois $7.7B AUM 11.59% 1-Year Est. Return
VestGen Advisors
VestGen Advisors Inverness, Illinois $3.25B AUM 30.95% 1-Year Est. Return
Choreo LLC
Choreo LLC Rockford, Illinois $9.7B AUM 18.43% 1-Year Est. Return
Foster Victor Wealth Advisors
Foster Victor Wealth Advisors Greenville, South Carolina $2.02B AUM 20.94% 1-Year Est. Return

TD Private Client Wealth's AVXL Position: Q3 2026 in Review

TD Private Client Wealth opened a new position in Anavex Life Sciences (AVXL) in Q3 2026: 229 shares worth $463. The stake represents ﹤0.01% of the portfolio and ranks #1655 among its holdings. This is a return to the name: TD Private Client Wealth previously reported a position in AVXL as recently as Q3 2021.

TD Private Client Wealth first reported a position in AVXL in Q1 2021 and has held it in 4 quarters since. The position peaked at $754 in Q2 2021. 43 funds tracked by Wall St. Rank hold AVXL as of Q3 2026.

  • TD Private Client Wealth held 229 shares of Anavex Life Sciences worth $463 as of Q3 2026.
  • Anavex Life Sciences was a new TD Private Client Wealth position in Q3 2026.
  • Anavex Life Sciences made up ﹤0.01% of TD Private Client Wealth's portfolio in Q3 2026, its #1655 holding.
  • TD Private Client Wealth first reported a position in Anavex Life Sciences in Q1 2021 and has held it in 4 quarters since.
  • TD Private Client Wealth's Anavex Life Sciences position peaked at $754 in Q2 2021.
  • 43 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q3 2026.

Based on TD Private Client Wealth's 13F filing for Q3 2026, filed 28 Oct 2026.